Filing Details
- Accession Number:
- 0000899243-20-018288
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-02 16:28:08
- Reporting Period:
- 2020-06-30
- Accepted Time:
- 2020-07-02 16:28:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1743881 | Bridgebio Pharma Inc. | BBIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1758363 | Cameron Turtle | C/O Bridgebio Pharma, Inc. 421 Kipling Street Palo Alto CA 94301 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-06-30 | 6,000 | $0.16 | 15,823 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2020-06-30 | 4,000 | $0.34 | 19,823 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-06-30 | 9,700 | $32.65 | 10,123 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-06-30 | 300 | $33.17 | 9,823 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-06-30 | 6,000 | $0.00 | 6,000 | $0.16 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-06-30 | 4,000 | $0.00 | 4,000 | $0.34 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
68,042 | 2020-05-19 | 2029-05-23 | No | 4 | M | Direct |
45,766 | 2020-05-19 | 2029-07-14 | No | 4 | M | Direct |
Footnotes
- Represents the weighted average sale price of the shares sold from $32.12 to $33.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2.
- Represents the weighted average sale price of the shares sold from $33.13 to $33.23 per share.